Trial of Excision Versus Photodynamic Therapy in the Treatment of Bowen's Disease

This study has been terminated.
(Study stopped because of disappointing inclusion rates)
Sponsor:
Collaborator:
Erasmus Medical Center
Information provided by:
Catharina Ziekenhuis Eindhoven
ClinicalTrials.gov Identifier:
NCT00472706
First received: May 10, 2007
Last updated: May 12, 2010
Last verified: May 2010

May 10, 2007
May 12, 2010
May 2007
February 2009   (final data collection date for primary outcome measure)
recurrence rate [ Time Frame: two years ] [ Designated as safety issue: No ]
recurrence rate [ Time Frame: two years ]
Complete list of historical versions of study NCT00472706 on ClinicalTrials.gov Archive Site
cosmetic outcome [ Time Frame: one year ] [ Designated as safety issue: No ]
cosmetic outcome [ Time Frame: one year ]
Not Provided
Not Provided
 
Trial of Excision Versus Photodynamic Therapy in the Treatment of Bowen's Disease
A Randomized Clinical Trial of Excision Versus Photodynamic Therapy in Bowen's Disease

The purpose of this study is to identify the most optimal therapy for Bowen's disease: excision versus Photodynamic therapy.

The study is a randomized clinical trial in which two treatment options for Bowen's disease, excision and photodynamic therapy, are compared on recurrence rate, cosmesis en expenses.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Bowen's Disease
  • Procedure: excision
    excision 3 mm margin
  • Procedure: Photodynamic therapy
    Photodynamic therapy
  • Active Comparator: 1
    Excision
    Intervention: Procedure: excision
  • Active Comparator: 2
    Photodynamic therapy
    Intervention: Procedure: Photodynamic therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
65
February 2010
February 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age > 18 years
  • Histological proven Bowen's disease on scalp, face, trunk, arms and legs
  • Informed Consent

Exclusion Criteria:

  • Recurrent Bowen's disease
  • Anogenital or subungual Bowe's disease
  • Other skin malignancy in the same area
  • Porphyria
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00472706
M06-16107
Yes
Drs. A. Verzijl, Catharina hospital/Erasmus MC
Catharina Ziekenhuis Eindhoven
Erasmus Medical Center
Principal Investigator: Annette Verzijl, MD Catharina hospital/Erasmus MC
Catharina Ziekenhuis Eindhoven
May 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP